Edgewise Therapeutics (EWTX) Price & Analysis

Compare

403 Followers

EWTX Stock Chart & Stats

$23.74

-$0.39(-1.54%)

At close: Jan 08 4:00 PM EST

$23.74

-$0.39(-1.54%)

Day’s Range― - ―

52-Week Range$10.60 - $35.50

Previous CloseN/A

Volume107.81K

Average Volume (3M)1.21M

Market Cap

$2.49B

Enterprise Value$1.15B

Total Cash (Recent Filing)$563.34M

Total Debt (Recent Filing)$4.18M

Price to Earnings (P/E)―

Beta2.38

Next Earnings

Feb 19, 2026

EPS Estimate

-0.44

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.39

Shares Outstanding105,868,430

10 Day Avg. Volume1,018,709

30 Day Avg. Volume1,213,361

Financial Highlights & Ratios

PEG Ratio2.41

Price to Book (P/B)5.37

Price to Sales (P/S)0.00

P/FCF Ratio-22.36

Enterprise Value/Market Cap0.46

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-6.68

Forecast

1Y Price Target

$37.00

Price Target Upside55.86% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical AdvancementsSevasemten is highlighted for its encouraging clinical results tied to functional benefits in BMD patients, positioning it as a strong first-in-class therapy.

Financial StrengthEdgewise ended the quarter financially strong with $563.3 million in cash.

Pipeline DevelopmentEdgewise is well-positioned to successfully advance its diverse pipeline of innovative small-molecule inhibitors, with upcoming data and program updates expected.

Bears Say

Market ConcernsShares dropped -33% as investors expressed concerns on the rates of atrial fibrillation (AFib) and potential differentiation versus competing cardiac myosin inhibitors (CMIs).

Regulatory And Competitive ChallengesFollowing the 3Q25 update, analyst is cutting sevasemten DMD estimates as there is a challenging regulatory/competitive backdrop likely taking greater time to resolve.

Uncertainty In Clinical And Regulatory PathwaysKey clinical and regulatory questions remain unanswered.

Edgewise Therapeutics News

Edgewise Therapeutics price target raised to $34 from $33 at JPMorgan

JPMorgan analyst Tessa Romero raised the firm’s price target on Edgewise Therapeutics (EWTX) to $34 from $33 and...

27d ago

EWTX

Edgewise Therapeutics Appoints Christopher Martin to Board

Edgewise Therapeutics ( ($EWTX) ) has shared an announcement. Edgewise Therapeutics announced the appointment of Christopher Martin to...

21d ago

EWTX

Edgewise Therapeutics Appoints New Chief Financial Officer

An announcement from Edgewise Therapeutics ( ($EWTX) ) is now available. On November 10, 2025, Edgewise Therapeutics announced...

1M ago

EWTX

Edgewise Therapeutics CFO Michael Carruthers to retire, Michael Nofi to succeed

Edgewise Therapeutics (EWTX) announced the appointment of Michael Nofi, as CFO, effective November 10. Nofi joins Edgewise after...

1M ago

EWTX

Edgewise Therapeutics Reports Q3 2025 Financial Results

Edgewise Therapeutics, Inc. ( ($EWTX) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

EWTX

Edgewise Therapeutics reports Q3 EPS (39c), consensus (40c)

Cash, cash equivalents and marketable securities were approximately $563.3M as of September 30. “With a strong balance sheet,...

1M ago

EWTX

Edgewise Therapeutics price target raised to $33 from $30 at JPMorgan

JPMorgan raised the firm’s price target on Edgewise Therapeutics (EWTX) to $33 from $30 and keeps an Overweight...

1M ago

EWTX

Edgewise Therapeutics Advances with Phase 1 Study of EDG-15400

Edgewise Therapeutics, Inc. (($EWTX)) announced an update on their ongoing clinical study. Edgewise Therapeutics, Inc. is conducting a...

2M ago

EWTX

Medpace and Edgewise Therapeutics Advance Becker Muscular Dystrophy Study

Medpace Holdings Inc (($MEDP)), Edgewise Therapeutics, Inc. (($EWTX)) announced an update on their ongoing clinical study. Medpace Holdings...

2M ago

EWTX

MEDP

Edgewise Therapeutics Advances EDG-7500 Study for Hypertrophic Cardiomyopathy

Edgewise Therapeutics, Inc. (($EWTX)) announced an update on their ongoing clinical study. Edgewise Therapeutics, Inc. is conducting a...

2M ago

EWTX

Edgewise Therapeutics’ EDG-7500 Study: A Potential Game Changer for Renal Impairment Treatment?

Edgewise Therapeutics, Inc. (($EWTX)) announced an update on their ongoing clinical study. Edgewise Therapeutics, Inc. is conducting a...

2M ago

EWTX

Promising Developments in Edgewise Therapeutics’ Sevasemten for Becker Muscular Dystrophy Earns Buy Rating

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Edgewise Therapeutics, with...

2M ago

EWTX

Cautious Neutral Rating for Edgewise Therapeutics Amid Clinical and Regulatory Uncertainties

Paul Choi, an analyst from Goldman Sachs, maintained the Hold rating on Edgewise Therapeutics. The associated price target...

3M ago

EWTX

Goldman Sachs assigns Neutral rating to Edgewise Therapeutics

Goldman Sachs assigned a Neutral rating and $20 price target to Edgewise Therapeutics (EWTX) after having previously covered...

3M ago

EWTX

EWTX FAQ

What was Edgewise Therapeutics’s price range in the past 12 months?

Edgewise Therapeutics lowest stock price was $10.60 and its highest was $35.50 in the past 12 months.

What is Edgewise Therapeutics’s market cap?

Edgewise Therapeutics’s market cap is $2.49B.

When is Edgewise Therapeutics’s upcoming earnings report date?

Edgewise Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 70 days.

How were Edgewise Therapeutics’s earnings last quarter?

Edgewise Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.397 by $0.007.

Is Edgewise Therapeutics overvalued?

According to Wall Street analysts Edgewise Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Edgewise Therapeutics pay dividends?

Edgewise Therapeutics does not currently pay dividends.

What is Edgewise Therapeutics’s EPS estimate?

Edgewise Therapeutics’s EPS estimate is -0.44.

How many shares outstanding does Edgewise Therapeutics have?

Edgewise Therapeutics has 105,868,430 shares outstanding.

What happened to Edgewise Therapeutics’s price movement after its last earnings report?

Edgewise Therapeutics reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.397. Following the earnings report the stock price went down -1.612%.

Which hedge fund is a major shareholder of Edgewise Therapeutics?

Currently, no hedge funds are holding shares in EWTX

Edgewise Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-30.02%

Trailing 12-Months

Asset Growth

14.12%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Edgewise Therapeutics

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Edgewise Therapeutics (EWTX) Earnings & Revenues

Historic Earnings Reports

EWTX Stock 12 Month Forecast

Average Price Target

$37.00

▲(55.86% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","52":"$52","21.25":"$21.3","31.5":"$31.5","41.75":"$41.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$51.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,21.25,31.5,41.75,52],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.27,27.24923076923077,29.228461538461538,31.20769230769231,33.18692307692308,35.16615384615385,37.145384615384614,39.12461538461538,41.103846153846156,43.08307692307692,45.0623076923077,47.041538461538465,49.02076923076923,{"y":51,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.27,26.17230769230769,27.074615384615385,27.976923076923075,28.87923076923077,29.78153846153846,30.683846153846154,31.586153846153845,32.488461538461536,33.39076923076923,34.293076923076924,35.19538461538461,36.097692307692306,{"y":37,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.27,24.864615384615384,24.459230769230768,24.053846153846152,23.64846153846154,23.243076923076924,22.837692307692308,22.432307692307692,22.026923076923076,21.62153846153846,21.216153846153844,20.810769230769232,20.405384615384616,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":31.54,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.02,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.17,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.68,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.44,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.28,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.27,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >